August 21, 2018
Article
Polycythemia vera is a myeloproliferative neoplasm characterized by clonal hematopoiesis and an absolute increase in the red blood cell mass, with an associated leukocytosis and thrombocytosis. Virtually all patients with PV harbor a mutation in the nonreceptor tyrosine kinase JAK2, with the majority of patients harboring the classic JAK2.
December 04, 2017
Video
John Mascarenhas, MD, associate professor, Icahn School of Medicine at Mount Sinai, discusses the role of JAK2 inhibition in patients with polycythemia vera (PV).
March 29, 2017
Video
John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a (Pegasys) with hydroxyurea in the treatment of patients with high-risk polycythemia vera (PV) and essential thrombocythemia (ET).
March 01, 2017
Video
John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses studies investigating pacritinib for the treatment of myelofibrosis.